$0.00
0.00% day before yesterday
Nasdaq, Aug 11, 03:30 pm CET
ISIN
US13089P1012
Symbol
CALA

Calithera Biosciences, Inc. Stock price

$0.00
+0.00 900.00% 1M
+0.00 66.67% 6M
+0.00 900.00% YTD
-0.05 98.00% 1Y
-4.11 99.98% 3Y
-82.20 100.00% 5Y
-112.00 100.00% 10Y
-188.20 100.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.00 0.00%
ISIN
US13089P1012
Symbol
CALA
Industry

Key metrics

Basic
Market capitalization
$0.0
Enterprise Value
$-25.5m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 0.0
P/S
- | -
EV/Sales
- | -
EV/FCF
0.6
P/B
0.0
Financial Health
Equity Ratio
71.1%
Return on Equity
-104.4%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-35.0m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | 16.7%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
8.9%
Employees
9
Rev per Employee
$0.0
Show more

Is Calithera Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Calithera Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Calithera Biosciences, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Calithera Biosciences, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Calithera Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '22
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
35% 35%
-
- Research and Development Expense 29 29
72% 72%
-
-42 -42
63% 63%
-
- Depreciation and Amortization 0.26 0.26
7% 7%
-
EBIT (Operating Income) EBIT -42 -42
63% 63%
-
Net Profit -21 -21
82% 82%
-

In millions USD.

Don't miss a Thing! We will send you all news about Calithera Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Susan Molineaux
Employees 9
Founded 2010
Website www.calithera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today